CA2837274C - Simian adenovirus and hybrid adenoviral vectors - Google Patents
Simian adenovirus and hybrid adenoviral vectors Download PDFInfo
- Publication number
- CA2837274C CA2837274C CA2837274A CA2837274A CA2837274C CA 2837274 C CA2837274 C CA 2837274C CA 2837274 A CA2837274 A CA 2837274A CA 2837274 A CA2837274 A CA 2837274A CA 2837274 C CA2837274 C CA 2837274C
- Authority
- CA
- Canada
- Prior art keywords
- vector
- ady25
- seq
- antigen
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1108879.6 | 2011-05-25 | ||
| GBGB1108879.6A GB201108879D0 (en) | 2011-05-25 | 2011-05-25 | Vector |
| PCT/GB2012/000467 WO2012172277A1 (en) | 2011-05-25 | 2012-05-25 | Simian adenovirus and hybrid adenoviral vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2837274A1 CA2837274A1 (en) | 2012-12-20 |
| CA2837274C true CA2837274C (en) | 2021-05-25 |
Family
ID=44279666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2837274A Active CA2837274C (en) | 2011-05-25 | 2012-05-25 | Simian adenovirus and hybrid adenoviral vectors |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9714435B2 (enExample) |
| EP (2) | EP2714916B1 (enExample) |
| JP (1) | JP6230527B2 (enExample) |
| CN (1) | CN103930551B (enExample) |
| AU (1) | AU2012270144B2 (enExample) |
| BR (1) | BR112013030222A2 (enExample) |
| CA (1) | CA2837274C (enExample) |
| DK (1) | DK2714916T3 (enExample) |
| ES (1) | ES2659183T3 (enExample) |
| FR (1) | FR21C1026I1 (enExample) |
| GB (1) | GB201108879D0 (enExample) |
| NO (2) | NO2714916T3 (enExample) |
| RU (1) | RU2013152648A (enExample) |
| SG (2) | SG195181A1 (enExample) |
| WO (1) | WO2012172277A1 (enExample) |
| ZA (1) | ZA201309016B (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201108879D0 (en) * | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| AU2013262626B2 (en) * | 2012-05-18 | 2018-11-29 | The Trustees Of The University Of Pennsylvania | Subfamily E simian adenoviruses A1302, A1320, A1331 and A1337 and uses thereof |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| GB201413530D0 (en) | 2014-07-30 | 2014-09-10 | Isis Innovation | Treatment and prevention of malaria |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| WO2016198621A1 (en) * | 2015-06-12 | 2016-12-15 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CN106916851A (zh) * | 2017-03-01 | 2017-07-04 | 广州恩宝生物医药科技有限公司 | 一种复制缺陷型人14型腺病毒载体及其制备方法和应用 |
| EP3595705A1 (en) | 2017-03-15 | 2020-01-22 | Oxford BioMedica (UK) Limited | Method |
| KR102945203B1 (ko) | 2017-05-08 | 2026-03-31 | 시애틀 프로젝트 코포레이션 | 알파바이러스 신생항원 벡터 |
| GB201708444D0 (en) | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Compositions and methods for inducing an immune response |
| KR20240134250A (ko) | 2018-01-04 | 2024-09-06 | 아이코닉 테라퓨틱스, 인코포레이티드 | 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법 |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| GB201812647D0 (en) * | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
| GB201814141D0 (en) * | 2018-08-30 | 2018-10-17 | Univ Oxford Innovation Ltd | Method and compositions for producing a virus |
| CN109797168A (zh) * | 2018-09-28 | 2019-05-24 | 广州佰芮慷生物科技有限公司 | 一种重组腺病毒的表达载体SAd23-L |
| EP3863666A2 (en) | 2018-10-10 | 2021-08-18 | Oxford University Innovation Limited | Treatment and prevention of malaria based on the antigen pfrh5 and antibodies against the same |
| GB201818084D0 (en) | 2018-11-06 | 2018-12-19 | Univ Oxford Innovation Ltd | Compositions and methods |
| KR20210090650A (ko) | 2018-11-07 | 2021-07-20 | 그릿스톤 바이오, 인코포레이티드 | 알파바이러스 신생항원 벡터 및 인터페론 억제제 |
| CN109602901B (zh) * | 2019-01-08 | 2022-05-27 | 成都迈科康生物科技有限公司 | 一种带状疱疹病毒疫苗及其制备方法和应用 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| US20220226459A1 (en) | 2019-05-22 | 2022-07-21 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| CN113924114A (zh) | 2019-05-22 | 2022-01-11 | 吉利德科学公司 | Tlr7调节化合物和hiv疫苗的组合 |
| SG11202113187WA (en) | 2019-05-30 | 2021-12-30 | Gritstone Bio Inc | Modified adenoviruses |
| CN113966228A (zh) * | 2019-06-11 | 2022-01-21 | 葛兰素史密斯克莱生物公司 | 黏膜疫苗配制剂 |
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗 |
| GB2594683A (en) | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| GB202003611D0 (en) | 2020-03-12 | 2020-04-29 | Univ Oxford Innovation Ltd | Stabilised viral fusion proteins |
| KR20220152248A (ko) | 2020-03-13 | 2022-11-15 | 옥스포드 유니버시티 이노베이션 리미티드 | 면역 반응을 유도하기 위한 조성물 및 방법 |
| RU2720614C9 (ru) * | 2020-04-23 | 2021-02-09 | федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации | Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты) |
| KR20230009445A (ko) | 2020-05-11 | 2023-01-17 | 얀센 파마슈티칼즈, 인코포레이티드 | 안정화된 코로나바이러스 스파이크 단백질 융합 단백질 |
| TWI867224B (zh) * | 2020-06-08 | 2024-12-21 | 中央研究院 | 重組抗體或片段，以及其用途 |
| EP4171627A1 (en) | 2020-06-29 | 2023-05-03 | Janssen Vaccines & Prevention B.V. | Vaccine combination against respiratory syncytial virus infection |
| BR112022026974A2 (pt) | 2020-07-06 | 2023-01-24 | Janssen Pharmaceuticals Inc | Proteínas de fusão estabilizadas de proteínas de pico de coronavírus |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| GB2596820A (en) | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
| IL300026A (en) | 2020-08-06 | 2023-03-01 | Gritstone Bio Inc | Multiepitope vaccine cassettes |
| RU2731356C9 (ru) * | 2020-08-22 | 2021-10-05 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты) |
| CA3192419A1 (en) | 2020-09-15 | 2022-03-24 | Adam Byrne | Treatment of idiopathic pulmonary fibrosis |
| GB202016604D0 (en) | 2020-10-20 | 2020-12-02 | Univ Of Oxford | Compositions and methods for inducing an immune response |
| GB202017673D0 (en) | 2020-11-09 | 2020-12-23 | Imperial College Innovations Ltd | Treatment of pulmonary arterial hypertensive |
| TW202237164A (zh) * | 2020-12-04 | 2022-10-01 | 美商磨石生物公司 | 組合物及其使用方法 |
| GB202019454D0 (en) | 2020-12-10 | 2021-01-27 | Chancellor Masters And Scholars Of The Univ Of Oxford | Method for purifying virus |
| GB202019455D0 (en) | 2020-12-10 | 2021-01-27 | Chancellor Masters And Scholars Of The Univ Of Oxford | Method for producing virus |
| US20240228548A9 (en) | 2021-02-19 | 2024-07-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
| KR20230150269A (ko) | 2021-02-23 | 2023-10-30 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 외피 단백질 돌연변이를 안정화시키는 삼량체 |
| AU2022249741A1 (en) | 2021-04-01 | 2023-09-21 | Msd International Business Gmbh | Stabilized pre-fusion piv3 f proteins |
| GB202105277D0 (en) | 2021-04-13 | 2021-05-26 | Imperial College Innovations Ltd | Signal peptides |
| WO2022234283A1 (en) | 2021-05-07 | 2022-11-10 | Astrazeneca Uk Limited | Compositions and methods for inducing an immune response |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023026182A1 (en) | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| EP4444347A1 (en) | 2021-12-07 | 2024-10-16 | Barinthus Biotherapeutics (UK) Limited | Vaccine boost methods and compositions |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| EP4448802A1 (en) | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| WO2023156505A1 (en) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l |
| WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
| EP4590690A1 (en) | 2022-09-23 | 2025-07-30 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
| WO2024074584A1 (en) | 2022-10-06 | 2024-04-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
| WO2024084441A1 (en) | 2022-10-19 | 2024-04-25 | Aelix Therapeutics, S.L. | Combination hiv vaccine |
| AU2023367778A1 (en) | 2022-10-25 | 2025-05-01 | Barinthus Biotherapeutics North America, Inc. | Combination treatment regimes for treating cancer |
| GB202301244D0 (en) | 2023-01-27 | 2023-03-15 | Univ Oxford Innovation Ltd | Vaccine |
| GB202303328D0 (en) | 2023-03-07 | 2023-04-19 | Imperial College Innovations Ltd | Synthetic promoters |
| GB202305535D0 (en) | 2023-04-14 | 2023-05-31 | Imperial College Innovations Ltd | Oligonucleotide decoy |
| WO2024218165A1 (en) | 2023-04-17 | 2024-10-24 | Barinthus Biotherapeutics (Uk) Limited | Hpv viral vector vaccine |
| WO2025017540A1 (en) | 2023-07-20 | 2025-01-23 | Aelix Therapeutics, S.L. | Method of treatment of hiv infection with vaccine |
| CN117089577B (zh) * | 2023-08-21 | 2024-06-25 | 暨南大学 | 重组的猴腺病毒、病毒载体及构建方法 |
| CN122319164A (zh) | 2023-09-05 | 2026-06-30 | 牛津大学创新有限公司 | 针对网织红细胞结合蛋白同源物5（pfrh5）的单克隆抗体 |
| GB202400424D0 (en) | 2024-01-11 | 2024-02-28 | Cancer Research Tech Ltd | Treatment and prevention of lung cancer |
| WO2025168946A1 (en) | 2024-02-09 | 2025-08-14 | Oxford University Innovation Limited | Pfrh5 immunogen |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3650939A (en) | 1964-11-12 | 1972-03-21 | Ppg Industries Inc | Alkali chlorine cell |
| CA2271450A1 (en) | 1999-05-12 | 2000-11-12 | Stuart Energy Systems Inc. | Hydrogen fuel replenishment process and apparatus |
| US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| MXPA04004876A (es) * | 2001-11-21 | 2004-07-30 | Univ Pennsylvania | Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso. |
| US20070205342A1 (en) | 2002-01-23 | 2007-09-06 | Edward Gabriel | Slip drive for leveling devices |
| US7481858B2 (en) | 2005-02-25 | 2009-01-27 | Societe Bic | Hydrogen generating fuel cell cartridges |
| JP4814800B2 (ja) * | 2004-01-23 | 2011-11-16 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | チンパンジーアデノウイルスワクチン担体 |
| US7617018B2 (en) | 2004-10-18 | 2009-11-10 | Innovative Design Solutions | Platform attitude adjustment augmentation method and apparatus |
| US7178337B2 (en) | 2004-12-23 | 2007-02-20 | Tassilo Pflanz | Power plant system for utilizing the heat energy of geothermal reservoirs |
| CN100578676C (zh) * | 2005-01-12 | 2010-01-06 | 明基电通股份有限公司 | 可调式升降支撑装置 |
| WO2007104792A2 (en) * | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| WO2007110409A1 (en) * | 2006-03-27 | 2007-10-04 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| AU2008262478B9 (en) * | 2007-05-29 | 2014-06-19 | Aldevron, L.L.C. | Vectors and methods for genetic immunization |
| KR101662574B1 (ko) * | 2007-11-28 | 2016-10-05 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38 |
| BRPI1009454A2 (pt) * | 2009-03-10 | 2019-09-24 | Baylor Res Institute | vacinas contra o câncer direcionadas a células apresentadoras de antígenos |
| GB201108879D0 (en) * | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
-
2011
- 2011-05-25 GB GBGB1108879.6A patent/GB201108879D0/en not_active Ceased
-
2012
- 2012-05-25 BR BR112013030222A patent/BR112013030222A2/pt not_active IP Right Cessation
- 2012-05-25 US US14/119,413 patent/US9714435B2/en active Active
- 2012-05-25 CN CN201280036659.1A patent/CN103930551B/zh active Active
- 2012-05-25 NO NO12723726A patent/NO2714916T3/no unknown
- 2012-05-25 EP EP12723726.1A patent/EP2714916B1/en active Active
- 2012-05-25 JP JP2014511948A patent/JP6230527B2/ja active Active
- 2012-05-25 SG SG2013087747A patent/SG195181A1/en unknown
- 2012-05-25 DK DK12723726.1T patent/DK2714916T3/en active
- 2012-05-25 WO PCT/GB2012/000467 patent/WO2012172277A1/en not_active Ceased
- 2012-05-25 CA CA2837274A patent/CA2837274C/en active Active
- 2012-05-25 RU RU2013152648/10A patent/RU2013152648A/ru not_active Application Discontinuation
- 2012-05-25 EP EP17204780.5A patent/EP3321367B1/en active Active
- 2012-05-25 ES ES12723726.1T patent/ES2659183T3/es active Active
- 2012-05-25 AU AU2012270144A patent/AU2012270144B2/en active Active
- 2012-05-25 SG SG10201604179VA patent/SG10201604179VA/en unknown
-
2013
- 2013-12-02 ZA ZA2013/09016A patent/ZA201309016B/en unknown
-
2017
- 2017-06-20 US US15/628,277 patent/US10646587B2/en active Active
-
2020
- 2020-04-15 US US16/849,301 patent/US11857640B2/en active Active
-
2021
- 2021-06-28 FR FR21C1026C patent/FR21C1026I1/fr active Active
- 2021-07-07 NO NO2021028C patent/NO2021028I1/no unknown
-
2023
- 2023-11-16 US US18/511,357 patent/US20240181078A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013030222A2 (pt) | 2016-12-06 |
| US20180000966A1 (en) | 2018-01-04 |
| EP3321367A3 (en) | 2018-07-25 |
| NO2021028I1 (no) | 2021-07-07 |
| US20150044766A1 (en) | 2015-02-12 |
| CA2837274A1 (en) | 2012-12-20 |
| DK2714916T3 (en) | 2018-02-19 |
| CN103930551B (zh) | 2017-05-24 |
| EP3321367A2 (en) | 2018-05-16 |
| SG10201604179VA (en) | 2016-07-28 |
| US20200360533A1 (en) | 2020-11-19 |
| AU2012270144B2 (en) | 2017-03-16 |
| NO2714916T3 (enExample) | 2018-06-09 |
| US11857640B2 (en) | 2024-01-02 |
| CN103930551A (zh) | 2014-07-16 |
| US9714435B2 (en) | 2017-07-25 |
| US20240181078A1 (en) | 2024-06-06 |
| ZA201309016B (en) | 2014-08-27 |
| SG195181A1 (en) | 2013-12-30 |
| EP3321367B1 (en) | 2021-09-29 |
| WO2012172277A4 (en) | 2013-04-04 |
| GB201108879D0 (en) | 2011-07-06 |
| ES2659183T3 (es) | 2018-03-14 |
| EP2714916A1 (en) | 2014-04-09 |
| US10646587B2 (en) | 2020-05-12 |
| JP2014516536A (ja) | 2014-07-17 |
| EP2714916B1 (en) | 2018-01-10 |
| WO2012172277A1 (en) | 2012-12-20 |
| FR21C1026I1 (fr) | 2021-08-06 |
| JP6230527B2 (ja) | 2017-11-15 |
| RU2013152648A (ru) | 2015-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240181078A1 (en) | Simian Adenovirus and Hybrid Adenoviral Vectors | |
| US12365920B2 (en) | Adenoviral vector | |
| AU2012270144A1 (en) | Simian adenovirus and hybrid adenoviral vectors | |
| JP7113924B2 (ja) | 組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）フィロウイルスワクチン | |
| CN107921118B (zh) | 腺病毒多核苷酸和多肽 | |
| CN110300597A (zh) | 腺病毒多核苷酸和多肽 | |
| HK40068020A (en) | Adenoviral vector | |
| HK40006989B (en) | Adenoviral vector | |
| JP7240390B2 (ja) | 増強されたプロモーター |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170228 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250519 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250519 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260423 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260423 |